Symptomatic Vocal Cord Paresis/Paralysis in Infants Operated on for Esophageal Atresia and/or Tracheo-Esophageal Fistula

Objectives To describe the prevalence and pathogenesis of symptomatic vocal cord paresis/paralysis (VCP) in patients treated for esophageal atresia (EA), tracheo-esophageal fistula (TEF) or both. Study design Retrospective study of all patients treated for EA/TEF in our center (1995 to 2009). Patien...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pediatrics Vol. 158; no. 6; pp. 973 - 976
Main Authors Morini, Francesco, MD, Iacobelli, Barbara D., MD, Crocoli, Alessandro, MD, Bottero, Sergio, MD, Trozzi, Marilena, MD, Conforti, Andrea, MD, Bagolan, Pietro, MD
Format Journal Article
LanguageEnglish
Published Maryland Heights, MO Mosby, Inc 01.06.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives To describe the prevalence and pathogenesis of symptomatic vocal cord paresis/paralysis (VCP) in patients treated for esophageal atresia (EA), tracheo-esophageal fistula (TEF) or both. Study design Retrospective study of all patients treated for EA/TEF in our center (1995 to 2009). Patients with and without symptomatic VCP were compared for gestational age, birth weight, associated anomalies, referrals, long-gap EA (>3cm or 3 vertebral bodies), cervical esophagostomy, anastomotic leakage, length of ventilation, and major cardiac surgery. Prevalence or median (IQR) is reported. Results Of 174 patients, 7 (4%) had symptomatic VCP. Prevalence of referrals (5/7 versus 21/167; P = .0009), long gap (5/7 versus 41/167; P = .0146), previous cervical esophagostomy (5/7 versus 7/167; P < .0001), and anastomotic leakage (3/7 versus 10/167; P = .0097) was higher, and ventilation longer (8.5 days [7.0 to 15.5] versus 6.0 days (5.0 to 7.0); P = .0072) in patients with VCP. Conclusions In infants treated for EA/TEF, VCP should be ruled out in case of persistent respiratory morbidity or, when present, cautiously monitored. Surgical risk factors should be actively controlled. Further studies are needed to define the prevalence of acquired and congenital VCP in patients with EA/TEF.
Bibliography:http://dx.doi.org/10.1016/j.jpeds.2010.12.006
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3476
1097-6833
DOI:10.1016/j.jpeds.2010.12.006